These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 26855006)

  • 1. Intensity-modulated radiotherapy or volumetric-modulated arc therapy in patients with head and neck cancer: Focus on salivary glands dosimetry.
    Vallard A; Guy JB; Mengue Ndong S; Vial N; Rivoirard R; Auberdiac P; Méry B; Langrand-Escure J; Espenel S; Moncharmont C; Ben Mrad M; Diao P; Goyet D; Magné N
    Head Neck; 2016 Jul; 38(7):1028-34. PubMed ID: 26855006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
    van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
    Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy requirements for head and neck intensity-modulated radiation therapy based on observed dose response of the major salivary glands.
    Kapanen M; Collan J; Saarilahti K; Heikkonen J; Kairemo K; Tenhunen M
    Radiother Oncol; 2009 Oct; 93(1):109-14. PubMed ID: 19435641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-effect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy.
    Murdoch-Kinch CA; Kim HM; Vineberg KA; Ship JA; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):373-82. PubMed ID: 18337023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective investigation and literature review of tolerance dose on salivary glands using quantitative salivary gland scintigraphy in the intensity-modulated radiotherapy era.
    Lee SW; Kang KW; Wu HG
    Head Neck; 2016 Apr; 38 Suppl 1():E1746-55. PubMed ID: 26875880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of organ-at-risk sparing and plan robustness for spot-scanning proton therapy and volumetric modulated arc photon therapy in head-and-neck cancer.
    Barten DL; Tol JP; Dahele M; Slotman BJ; Verbakel WF
    Med Phys; 2015 Nov; 42(11):6589-98. PubMed ID: 26520750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
    Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study on the impact of patient-related parameters in the ability to spare parotid glands by intensity-modulated radiotherapy for head and neck squamous cell carcinomas.
    Bandlamudi BP; Sharan K; Yathiraj PH; Singh A; Reddy A; Fernandes DJ; Srinivasa VM
    J Cancer Res Ther; 2018; 14(6):1220-1224. PubMed ID: 30488833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dose to parotid ducts on Sticky Saliva and Xerostomia in radiotherapy of head and neck squamous cell carcinoma.
    Schanne DH; Alder DU; Lippmann J; Aebersold DM; Elicin O
    Radiat Oncol; 2024 Aug; 19(1):104. PubMed ID: 39095864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer.
    Eisbruch A; Ship JA; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Hogikyan ND; Anzai Y; Marsh LH; Ten Haken RK; Wolf GT
    World J Surg; 2003 Jul; 27(7):832-7. PubMed ID: 14509515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of treatment techniques for reduction in the submandibular gland dose: A retrospective study.
    Hoyne C; Dreosti M; Shakeshaft J; Baxi S
    J Med Radiat Sci; 2017 Jun; 64(2):125-130. PubMed ID: 28240447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sparing the contralateral submandibular gland without compromising PTV coverage by using volumetric modulated arc therapy.
    Doornaert P; Verbakel WF; Rietveld DH; Slotman BJ; Senan S
    Radiat Oncol; 2011 Jun; 6():74. PubMed ID: 21679401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Submandibular gland-sparing intensity modulated radiotherapy in the treatment of head and neck cancer: sites of locoregional relapse and survival.
    Collan J; Kapanen M; Mäkitie A; Nyman H; Joensuu H; Tenhunen M; Saarilahti K
    Acta Oncol; 2012 Jul; 51(6):735-42. PubMed ID: 22150115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.
    Tam M; Riaz N; Kannarunimit D; Peña AP; Schupak KD; Gelblum DY; Wolden SL; Rao S; Lee NY
    Am J Clin Oncol; 2015 Aug; 38(4):343-7. PubMed ID: 26208401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of submandibular salivary gland transfer and intensity-modulated radiotherapy to reduce dryness of mouth (xerostomia) in patients with head and neck cancer.
    Scrimger RA; Seikaly H; Vos LJ; Harris J; O'Connell D; Ghosh S; Debenham B; Jha N
    Head Neck; 2018 Nov; 40(11):2353-2361. PubMed ID: 30175876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.